Unknown

Dataset Information

0

Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.


ABSTRACT: Neutralizing antibodies (NAb) against autologous virus can reach high titers in human immunodeficiency virus type 1 (HIV-1)-infected patients with progressive disease. Less is known about the role of NAb in HIV-1-infected patients with viral loads of <50 copies/ml of plasma, including patients on effective highly active antiretroviral therapy (HAART) and elite suppressors, who control HIV-1 replication without antiretroviral therapy. In this study, we analyzed full-length env sequences from plasma viruses and proviruses in resting CD4(+) T cells of HAART-treated patients, elite suppressors, and untreated HIV-1-infected patients with progressive disease. For each patient group, we assessed plasma virus neutralization by autologous, contemporaneous plasma. The degree of env diversity, the number of N-linked glycosylation sites, and the lengths of variable loops were all lower in elite suppressors than in HAART-treated and untreated viremic patients. Both elite suppressors and HAART-treated patients had lower titers of NAb against HIV-1 lab strains than those of untreated viremic patients. Surprisingly, titers of NAb against autologous, contemporaneous plasma viruses were similarly low in chronic progressors, elite suppressors, and HAART-treated patients. In elite suppressors and HAART-treated patients, titers of NAb against autologous plasma viruses also did not differ significantly from titers against autologous proviruses from resting CD4(+) T cells. These results suggest that high-titer NAb are not required for maintenance of viral suppression in elite suppressors and that NAb do not select plasma virus variants in most HAART-treated patients. Both drug-mediated and natural suppression of HIV-1 replication to levels below 50 copies/ml may limit the stimulation and maintenance of effective NAb responses.

SUBMITTER: Bailey JR 

PROVIDER: S-EPMC1472047 | biostudies-literature | 2006 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.

Bailey Justin R JR   Lassen Kara G KG   Yang Hung-Chih HC   Quinn Thomas C TC   Ray Stuart C SC   Blankson Joel N JN   Siliciano Robert F RF  

Journal of virology 20060501 10


Neutralizing antibodies (NAb) against autologous virus can reach high titers in human immunodeficiency virus type 1 (HIV-1)-infected patients with progressive disease. Less is known about the role of NAb in HIV-1-infected patients with viral loads of <50 copies/ml of plasma, including patients on effective highly active antiretroviral therapy (HAART) and elite suppressors, who control HIV-1 replication without antiretroviral therapy. In this study, we analyzed full-length env sequences from plas  ...[more]

Similar Datasets

| S-EPMC2612349 | biostudies-literature
| S-EPMC4304674 | biostudies-literature
| S-EPMC189045 | biostudies-literature
| S-EPMC1865922 | biostudies-literature
| S-EPMC2259015 | biostudies-literature
| S-EPMC8329590 | biostudies-literature
| S-EPMC2224433 | biostudies-literature
| S-EPMC3799352 | biostudies-other
| S-EPMC2612327 | biostudies-literature
| S-EPMC8508778 | biostudies-literature